|Institutional Source||Beutler Lab|
|Gene Name||adaptor-related protein complex 3, beta 2 subunit|
|Is this an essential gene?||Probably non essential (E-score: 0.117)|
|Stock #||R1489 (G1)|
|Chromosomal Location||81460399-81493925 bp(-) (GRCm38)|
|Type of Mutation||nonsense|
|DNA Base Change (assembly)||C to A at 81463690 bp|
|Amino Acid Change||Glutamic Acid to Stop codon at position 924 (E924*)|
|Ref Sequence||ENSEMBL: ENSMUSP00000080739 (fasta)|
|Gene Model||predicted gene model for transcript(s): [ENSMUST00000082090]|
|Predicted Effect||probably null
AA Change: E924*
AA Change: E924*
|Predicted Effect||noncoding transcript
|Meta Mutation Damage Score||0.9755|
|Coding Region Coverage||
|Validation Efficiency||96% (52/54)|
FUNCTION: [Summary is not available for the mouse gene. This summary is for the human ortholog.] Adaptor protein complex 3 (AP-3 complex) is a heterotrimeric protein complex involved in the formation of clathrin-coated synaptic vesicles. The protein encoded by this gene represents the beta subunit of the neuron-specific AP-3 complex and was first identified as the target antigen in human paraneoplastic neurologic disorders. The encoded subunit binds clathrin and is phosphorylated by a casein kinase-like protein, which mediates synaptic vesicle coat assembly. Defects in this gene are a cause of early-onset epileptic encephalopathy. [provided by RefSeq, Feb 2017]
PHENOTYPE: Disruption does not alter pigmentation, but causes hyperactivity and tonic-clonic seizures and mice homozygous for a knock-out allele were found to have significantly reduced synaptic zinc levels throughout the brain, with the largest reduction observed in the CA1 stratum oriens. [provided by MGI curators]
|Allele List at MGI|
|Other mutations in this stock||
|Other mutations in Ap3b2||
(F):5'- AATGTGCTCAAAGACCTCCTGCCC -3'
(R):5'- TCTCTAGCTGCTGAGTCCAGTGTC -3'
(F):5'- CCTGCCCTAATAGGAACTTGC -3'
(R):5'- CAGTGTCCAGCATTGGGAG -3'